UPDATE: Important information about LabCorp's response to COVID-19 Read more >>>

News Release

Printer Friendly Version View printer-friendly version
<< Back
Amy Summy, Chief Marketing Officer of Labcorp, Named to Forbes’ CMO Next

BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 16, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that Amy Summy, executive vice president and chief marketing officer, was recognized on the 2021 Forbes CMO Next list for her leadership during the COVID-19 crisis, while also spearheading the rebranding strategy that highlighted the power of Labcorp’s combined diagnostic and drug development businesses. Forbes also recognized Amy’s work in launching several products, including the company’s Pixel by Labcorp™ at-home testing kits.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216006013/en/

Amy Summy, CMO, Labcorp (Photo: Business Wire)

Amy Summy, CMO, Labcorp (Photo: Business Wire)

CMO Next features 50 chief marketing officers who are redefining the role that marketing plays in their industries. Selected by editors and outside experts, Forbes CMO Next highlights leaders that serve as role models in the areas of innovation, technology, creativity, and culture.

“Making an impact on healthcare and people’s lives is why I joined Labcorp,” said Summy. “Over 75,000 Labcorp employees have served on the frontlines fighting COVID-19, and our leadership in testing and clinical trial capabilities has played a central role during this unprecedented time. I am honored to be recognized by Forbes and share this accomplishment with our team for focusing on bringing the innovation and scientific expertise of Labcorp to market quickly so we can improve health and improve lives. I look forward to building on our foundation and working with our teams to improve patient outcomes in cancer, Alzheimer’s and other diseases.”

Summy joined Labcorp after serving in marketing, digital and leadership roles at Ernst & Young, TE Connectivity and Sapient. She is the co-founder and board member of No More Kids with Cancer and is a member of the Corporate Council for the Children’s Hospital of Philadelphia. Her teams have played an important role in Labcorp’s worldwide response to COVID-19 and recently launched Labcorp’s new brand, which exemplifies the role Labcorp plays in guiding health, and its commitment to improving health and improving lives.

The complete list and profiles of the honorees are available at https://www.forbes.com/sites/martyswant/2021/02/11/cmo-next-2021-50-innovative-marketers-transforming-business-in-a-changed-world/?sh=445ab84a571e.

About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to recognition and reputation of the Company. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, the COVID-19 pandemic and its impact on our business and financial condition as well as general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, the effect of public opinion on the Company’s reputation, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, the number of revenue days in a financial period, personnel costs, and the effect of exchange rate fluctuations, and employee relations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.

###

Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com

Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com

Source: Labcorp